15 completed. 15 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 15 |
| Phase 2 | 3 | Completed 3 |
Follow Thyroid Eye Disease: new trials by email Literature Review of Thyroid Eye Disease trials Research Report on Thyroid Eye Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) VRDN-003, Autoinjector - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 87 | 2025-07-01 | 2026-06-25 |
| A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) Veligrotug - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 231 | 2024-05-23 | 2026-08-13 |
| An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 Veligrotug - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 139 | 2024-01-31 | 2026-08-14 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease Satralizumab, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Hoffmann-La Roche | 127 | 2023-11-15 | 2026-08-12 |
| An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) Veligrotug, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 188 | 2023-11-01 | 2026-08-13 |
| Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease Satralizumab, Placebo - Thyroid Eye Disease, TED | Phase 3 | Completed | Hoffmann-La Roche | 131 | 2023-10-26 | 2026-07-31 |
| A Study of IBI311 in Subjects With Active Thyroid Eye Disease IBI311, placebo - Thyroid Eye Disease | Phase 2 / Phase 3 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 115 | 2023-02-14 | 2024-02-08 |
| Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Batoclimab, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Immunovant Sciences GmbH | 86 | 2023-01-05 | 2026-04-01 |
| Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Batoclimab, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Immunovant Sciences GmbH | 114 | 2022-11-23 | 2025-12-03 |
| A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED) Veligrotug, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 113 | 2022-11-16 | 2026-08-13 |
| A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Linsitinib, Placebo - Thyroid Eye Disease, Graves Orbitopathy | Phase 2 / Phase 3 | Completed | Sling Therapeutics, Inc. | 90 | 2022-07-01 | 2026-09-23 |
| Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease peri-levator betamethasone injection, peri-levator triamcinolone injection, peri-levator and retrobulbar betamethasone injection - Thyroid Eye Disease | Phase 2 / Phase 3 | Completed | Assiut University | 92 | 2021-12-01 | 2023-11-14 |
| Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study Teprotumumab - Thyroid Eye Disease | Phase 3 | Completed | Amgen | 51 | 2018-04-16 | 2024-06-28 |
| Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study Teprotumumab, Placebo - Thyroid Eye Disease, Graves' Orbitopathy | Phase 3 | Completed | Amgen | 83 | 2017-10-04 | 2024-07-11 |
| Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) Tocilizumab (RoActemra®), Sterile 0.9% Sodium Chloride - Thyroid Associated Ophthalmopathies, Graves´ Ophthalmopathy | Phase 3 | Completed | Hospital Clinico Universitario de Santiago | 32 | 2012-03-01 | 2016-01-20 |
Graves Ophthalmopathy (15) · Graves Disease (4) · Autoimmune Diseases (2) · Exophthalmos (2) · Endocrine System Diseases (1) · Eye Diseases (1) · Hashimoto Disease (1) · Orbital Diseases (1) · Thyroid Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15) · Eye Diseases, Hereditary (15) · Genetic Diseases, Inborn (15) · Goiter (15) · Hyperthyroidism (15) · Immune System Diseases (15) · Endocrine System Diseases (14) · Eye Diseases (14) · Orbital Diseases (14) · Thyroid Diseases (14) · Autoimmune Diseases (13) · Exophthalmos (13) · Graves Disease (11) · Thyroiditis (1) · Thyroiditis, Autoimmune (1)
satralizumab (2) · teprotumumab (2) · 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (1) · Saline Solution (1) · Sodium Chloride (1) · tocilizumab (1)
Viridian Therapeutics, Inc. (5) · Amgen (2) · Hoffmann-La Roche (2) · Immunovant Sciences GmbH (2) · Assiut University (1) · Hospital Clinico Universitario de Santiago (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Sling Therapeutics, Inc. (1)
United States (12) · Germany (9) · Spain (8) · United Kingdom (7) · Poland (6) · Australia (5) · France (5) · Italy (5) · Canada (3) · Hungary (3) · Turkey (Türkiye) (3) · China (2) · Israel (2) · Japan (2) · Argentina (1)
Ahmed Abdelal, MD (1) · Mohamed Shehata, MD (1) · Salma Kedwany, MD (1)
PMID 41066062, PMID 27797318, PMID 31971679, PMID 33172865, PMID 33768488, PMID 41066129
2017 (2), 2023 (2)